3 not yet recruiting, 3 recruiting, 2 completed, 1 terminated. 9 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Not yet recruiting 3, Recruiting 3, Completed 2, Terminated 1 |
| Phase 1 | 3 | Completed 1, Not yet recruiting 1, Recruiting 1 |
Follow Sjogren Syndrome: new trials by email Literature Review of Sjogren Syndrome trials Research Report on Sjogren Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Topical Infliximab in Autoimmune Dry Eye Disease Infliximab 0.1%, Loteprednol - Sjogren Syndrome, Sjogren Syndrome With Keratoconjunctivitis | Phase 2 | Not yet recruiting | Instituto de Oftalmología Fundación Conde de Valenciana | 38 | 2026-12-01 | 2026-06-26 |
| Exosome and Mesenchymal Stem Cell Treatment for Salivary Gland Dysfunction in Primary Sjögren Syndrome exosomes derived from human umbilical cord mesenchymal stem cells, Mesenchymal Stem Cells (MSC), Placebo - Sjogren Syndrome, Xerostomia | Phase 2 | Not yet recruiting | Banu Erkal | 30 | 2026-12-01 | 2026-09-24 |
| Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Not yet recruiting | Peking University Third Hospital | 9 | 2026-11-01 | 2026-09-23 |
| AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. Allogeneic NK Cells - Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs) | Phase 2 | Recruiting | Artiva Biotherapeutics, Inc. | 90 | 2025-07-09 | 2026-07-31 |
| Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases anti-CD19 CAR T cell therapy - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Recruiting | Peking University Third Hospital | 9 | 2025-07-01 | 2026-09-22 |
| BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases BCMA-CD19 CAR-T therapy - Systemic Lupus Erythematosus, Inflammatory Myopathy | Phase 2 | Recruiting | Peking University People's Hospital | 50 | 2024-12-26 | 2025-04-02 |
| Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments. Ianalumab - Sjogren Syndrome | Phase 2 | Completed | Novartis Pharmaceuticals | 21 | 2022-07-27 | 2026-02-02 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD) MHV370, Placebo - Sjogren Syndrome, Mixed Connective Tissue Disease | Phase 2 | Terminated | Novartis Pharmaceuticals | 30 | 2021-11-30 | 2024-10-09 |
| Green Tea Lozenges for the Management of Dry Mouth MighTeaFlow, Xylitol - Xerostomia, Sjogren Syndrome | Phase 1 / Phase 2 | Completed | Augusta University | 60 | 2011-03-01 | 2015-03-18 |
Sjogren's Syndrome (9) · Myositis (4) · Scleroderma, Systemic (4) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3) · Xerostomia (3) · Antiphospholipid Syndrome (2) · Dry Eye Syndromes (2) · Arthritis, Rheumatoid (1) · Behcet Syndrome (1) · Immunoglobulin G4-Related Disease (1) · Lupus Erythematosus, Systemic (1) · Mixed Connective Tissue Disease (1) · Purpura, Thrombotic Thrombocytopenic (1) · Scleroderma, Diffuse (1)
Arthritis (9) · Autoimmune Diseases (9) · Connective Tissue Diseases (9) · Eye Diseases (9) · Immune System Diseases (9) · Joint Diseases (9) · Lacrimal Apparatus Diseases (9) · Mouth Diseases (9) · Musculoskeletal Diseases (9) · Rheumatic Diseases (9) · Salivary Gland Diseases (9) · Skin and Connective Tissue Diseases (9) · Stomatognathic Diseases (9) · Arthritis, Rheumatoid (8) · Dry Eye Syndromes (7)
Aspartame (1) · Infliximab (1) · Loteprednol Etabonate (1) · Xylitol (1) · ianalumab (1)
Novartis Pharmaceuticals (2) · Peking University Third Hospital (2) · Artiva Biotherapeutics, Inc. (1) · Augusta University (1) · Banu Erkal (1) · Instituto de Oftalmología Fundación Conde de Valenciana (1) · Peking University People's Hospital (1)
China (3) · France (2) · Germany (2) · Poland (2) · Spain (2) · United States (2) · Brazil (1) · Bulgaria (1) · Hungary (1) · Italy (1) · Mexico (1) · Portugal (1) · Romania (1) · Serbia (1) · Taiwan (1)
Banu Erkal, Resident (1) · Enrique Graue-Hernandez, MD, MSc (1) · Michael Saddekni, M.D., PgDip, BCMAS (1) · Scott S De Rossi, DMD (1) · Yavuz Selim Pata, Professor (1) · Zhanguo Li (1)
PMID 25240992, PMID 40747756, PMID 40787733, PMID 41726564
2023 (1)